{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+IB&page=18",
    "query": {
      "condition": "Phase IB",
      "page": 18
    },
    "page_size": 10
  },
  "pagination": {
    "page": 18,
    "page_size": 10,
    "total_count": 1612,
    "total_pages": 162,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+IB&page=19&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+IB&page=17&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-07T19:28:01.659Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04081389",
      "title": "Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Anatomic Stage 0 Breast Cancer AJCC v8",
        "Anatomic Stage I Breast Cancer AJCC v8",
        "Anatomic Stage IA Breast Cancer AJCC v8",
        "Anatomic Stage IB Breast Cancer AJCC v8",
        "Anatomic Stage II Breast Cancer AJCC v8",
        "Anatomic Stage IIA Breast Cancer AJCC v8",
        "Anatomic Stage IIB Breast Cancer AJCC v8",
        "Early-Stage Breast Carcinoma",
        "Estrogen Receptor Negative",
        "HER2/Neu Negative",
        "Progesterone Receptor Negative",
        "Prognostic Stage 0 Breast Cancer AJCC v8",
        "Prognostic Stage I Breast Cancer AJCC v8",
        "Prognostic Stage IA Breast Cancer AJCC v8",
        "Prognostic Stage IB Breast Cancer AJCC v8",
        "Prognostic Stage II Breast Cancer AJCC v8",
        "Prognostic Stage IIA Breast Cancer AJCC v8",
        "Prognostic Stage IIB Breast Cancer AJCC v8",
        "Triple-Negative Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "Celecoxib",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Recombinant Interferon Alfa-2b",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Rintatolimod",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2019-12-06",
      "completion_date": "2023-02-27",
      "has_results": true,
      "last_update_posted_date": "2023-09-11",
      "last_synced_at": "2026-11-07T19:28:01.659Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04081389"
    },
    {
      "nct_id": "NCT01041027",
      "title": "Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Endometrial Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Endometrial Adenocarcinoma",
        "Stage IA Uterine Corpus Cancer",
        "Stage IB Uterine Corpus Cancer",
        "Stage II Uterine Corpus Cancer",
        "Stage IIIA Uterine Corpus Cancer",
        "Stage IIIB Uterine Corpus Cancer",
        "Stage IIIC Uterine Corpus Cancer",
        "Stage IVA Uterine Corpus Cancer",
        "Stage IVB Uterine Corpus Cancer"
      ],
      "interventions": [
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Internal Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "External Beam Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "OTHER"
      ],
      "sponsor": "Albert Einstein College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 31,
      "start_date": "2009-01-16",
      "completion_date": "2019-10-01",
      "has_results": true,
      "last_update_posted_date": "2023-10-26",
      "last_synced_at": "2026-11-07T19:28:01.659Z",
      "location_count": 1,
      "location_summary": "The Bronx, New York",
      "locations": [
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01041027"
    },
    {
      "nct_id": "NCT03458546",
      "title": "Study of Roflumilast in Combination With Standard Chemotherapy for High-risk Diffuse Large B-cell Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lymphoma, B-Cell"
      ],
      "interventions": [
        {
          "name": "Roflumilast",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The University of Texas Health Science Center at San Antonio",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2018-05-21",
      "completion_date": "2024-01-16",
      "has_results": false,
      "last_update_posted_date": "2024-02-21",
      "last_synced_at": "2026-11-07T19:28:01.659Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03458546"
    },
    {
      "nct_id": "NCT02186470",
      "title": "Intensity Modulated Accelerated Partial Breast Irradiation Before Surgery in Treating Older Patients With Hormone Responsive Stage 0-I Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Estrogen Receptor-positive Breast Cancer",
        "Invasive Ductal Breast Carcinoma",
        "Invasive Ductal Breast Carcinoma With Predominant Intraductal Component",
        "Medullary Ductal Breast Carcinoma With Lymphocytic Infiltrate",
        "Mucinous Ductal Breast Carcinoma",
        "Papillary Ductal Breast Carcinoma",
        "Progesterone Receptor-positive Breast Cancer",
        "Stage IA Breast Cancer",
        "Stage IB Breast Cancer",
        "Tubular Ductal Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "accelerated partial breast irradiation",
          "type": "RADIATION"
        },
        {
          "name": "intensity-modulated radiation therapy",
          "type": "RADIATION"
        },
        {
          "name": "image-guided radiation therapy",
          "type": "RADIATION"
        },
        {
          "name": "therapeutic conventional surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "PROCEDURE"
      ],
      "sponsor": "Ohio State University Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "50 Years and older · Female only"
      },
      "enrollment_count": 22,
      "start_date": "2016-04-29",
      "completion_date": "2025-09-04",
      "has_results": false,
      "last_update_posted_date": "2025-09-22",
      "last_synced_at": "2026-11-07T19:28:01.659Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02186470"
    },
    {
      "nct_id": "NCT02891161",
      "title": "Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 N0-2 M0) of the Bladder",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Urothelial Cancer"
      ],
      "interventions": [
        {
          "name": "durvalumab",
          "type": "DRUG"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Monika Joshi, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2016-11-16",
      "completion_date": "2022-04-27",
      "has_results": true,
      "last_update_posted_date": "2024-11-27",
      "last_synced_at": "2026-11-07T19:28:01.659Z",
      "location_count": 7,
      "location_summary": "Iowa City, Iowa • Omaha, Nebraska • New Brunswick, New Jersey + 4 more",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        },
        {
          "city": "Hershey",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02891161"
    },
    {
      "nct_id": "NCT01660750",
      "title": "A Safety Study of Carfilzomib, Cyclophosphamide & Dexamethasone Prior to ASCT in Patients With Newly Diagnosed Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Carfilzomib",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Criterium, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 29,
      "start_date": "2013-01",
      "completion_date": "2015-12",
      "has_results": false,
      "last_update_posted_date": "2017-10-18",
      "last_synced_at": "2026-11-07T19:28:01.659Z",
      "location_count": 5,
      "location_summary": "Los Angeles, California • Palm Springs, California • Worcester, Massachusetts + 2 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palm Springs",
          "state": "California"
        },
        {
          "city": "Worcester",
          "state": "Massachusetts"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01660750"
    },
    {
      "nct_id": "NCT05025059",
      "title": "Exercise During Chemotherapy in Older Women With Stage I-III Breast Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Anatomic Stage I Breast Cancer AJCC v8",
        "Anatomic Stage IA Breast Cancer AJCC v8",
        "Anatomic Stage IB Breast Cancer AJCC v8",
        "Anatomic Stage II Breast Cancer AJCC v8",
        "Anatomic Stage IIA Breast Cancer AJCC v8",
        "Anatomic Stage IIB Breast Cancer AJCC v8",
        "Anatomic Stage III Breast Cancer AJCC v8",
        "Anatomic Stage IIIA Breast Cancer AJCC v8",
        "Anatomic Stage IIIB Breast Cancer AJCC v8",
        "Anatomic Stage IIIC Breast Cancer AJCC v8",
        "Prognostic Stage I Breast Cancer AJCC v8",
        "Prognostic Stage IA Breast Cancer AJCC v8",
        "Prognostic Stage IB Breast Cancer AJCC v8",
        "Prognostic Stage II Breast Cancer AJCC v8",
        "Prognostic Stage IIA Breast Cancer AJCC v8",
        "Prognostic Stage IIB Breast Cancer AJCC v8",
        "Prognostic Stage III Breast Cancer AJCC v8",
        "Prognostic Stage IIIA Breast Cancer AJCC v8",
        "Prognostic Stage IIIB Breast Cancer AJCC v8",
        "Prognostic Stage IIIC Breast Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Discussion",
          "type": "PROCEDURE"
        },
        {
          "name": "Exercise Intervention",
          "type": "OTHER"
        },
        {
          "name": "Informational Intervention",
          "type": "OTHER"
        },
        {
          "name": "Medical Device Usage and Evaluation",
          "type": "OTHER"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "65 Years and older · Female only"
      },
      "enrollment_count": 30,
      "start_date": "2020-12-03",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-14",
      "last_synced_at": "2026-11-07T19:28:01.659Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05025059"
    },
    {
      "nct_id": "NCT03641755",
      "title": "Olaparib + Sapacitabine in BRCA Mutant Breast Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Sapacitabine",
          "type": "DRUG"
        },
        {
          "name": "Olaparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2018-10-01",
      "completion_date": "2026-10-22",
      "has_results": false,
      "last_update_posted_date": "2026-02-23",
      "last_synced_at": "2026-11-07T19:28:01.659Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts • Cambridge, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Cambridge",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03641755"
    },
    {
      "nct_id": "NCT06395285",
      "title": "Evaluating the Safety and Tolerability of Orally Administered DF-003 in ROSAH Syndrome Patients",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "ROSAH"
      ],
      "interventions": [
        {
          "name": "DF-003",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shanghai Yao Yuan Biotechnology Ltd. (also known as Drug Farm)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 12,
      "start_date": "2025-05-27",
      "completion_date": "2026-11",
      "has_results": false,
      "last_update_posted_date": "2026-06-05",
      "last_synced_at": "2026-11-07T19:28:01.659Z",
      "location_count": 3,
      "location_summary": "Bethesda, Maryland • Durham, North Carolina • Salt Lake City, Utah",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06395285"
    },
    {
      "nct_id": "NCT02124850",
      "title": "A Phase Ib Study of Neoadjuvant of Cetuximab Plus Motolimod and Cetuximab Plus Motolimod Plus Nivolumab",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Squamous Cell Carcinoma of the Head and Neck"
      ],
      "interventions": [
        {
          "name": "Motolimod",
          "type": "DRUG"
        },
        {
          "name": "Cetuximab",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2014-10-28",
      "completion_date": "2016-10-31",
      "has_results": false,
      "last_update_posted_date": "2019-10-25",
      "last_synced_at": "2026-11-07T19:28:01.659Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02124850"
    }
  ]
}